|
hiren379 ★ India, 2012-09-11 08:09 (5031 d 23:59 ago) (edited on 2012-09-11 08:58) Posting: # 9170 Views: 7,663 |
|
|
Hello friends, OGD recomendation for Iron Sucrose Injection suggest Parallel design even though the half life is around 6-7 hrs. What can be the rationale for it? ![]() ![]() Along with it they also recommend reference replicate design if one suspects high variability. Can anyone explain the stand/thinking of USFDA on this? Regards, Hiren |
|
auditor ★ India, 2012-09-11 13:31 (5031 d 18:37 ago) @ hiren379 Posting: # 9176 Views: 6,786 |
|
|
Dear, we are facing same problem and searching for same too. ![]() ![]() hope we will get answer from anyone of the forum. thanks, |
|
drgunasakaran1 ★★ 2012-09-12 16:40 (5030 d 15:28 ago) @ hiren379 Posting: # 9186 Views: 6,936 |
|
|
Dear Mr Hiren, ❝ OGD recomendation for Iron Sucrose Injection suggest Parallel design even though the half life is around 6-7 hrs. What can be the rationale for it? Kindly be informed that we need to estimate Total Iron as well as Transferrin Bound Iron for Bioequivalence evaluation of Iron Sucrose BE study as per FDA's Individual Product Recommendation on Iron Sucrose. FDA's Suggestion for Parallel design is not based on the half life of the iron which is around 6 hours. But, FDA's recommendation on Parallel design is based on the Long time taken to eliminate the Transferrin Bound Iron from the body. ❝ ❝ Along with it they also recommend reference replicate design if one suspects high variability. The pharmacokinetics parameters of Total Iron/Transferrin Bound Iron has high Intrasubject Variability. Hence, FDA is suggesting for Reference-scaled average bioequivalence approach. — Dr Gunasakaran Sambandan MD Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn |
|
hiren379 ★ India, 2012-09-12 17:35 (5030 d 14:34 ago) @ drgunasakaran1 Posting: # 9189 Views: 6,958 |
|
|
Dear Dr ❝ Kindly be informed that we need to estimate Total Iron as well as Transferrin Bound Iron for Bioequivalence evaluation of Iron Sucrose BE study as per I have already referred OGD of Iron Sucrose and do know about the analytes to be measured... ❝ FDA's recommendation on Parallel design is based on the Long time taken to eliminate the Transferrin Bound Iron from the body. Can you provide literature for the same as I have different understanding based on literature available to me????
![]() Regards, Hiren |


![[image]](img/uploaded/image36.jpg)
